免疫查核點抑制劑市場規模、佔有率及成長分析（按類型、應用、通路和地區）- 2025-2032 年產業預測

2023 年全球免疫查核點抑制劑市場規模價值為 484.7 億美元，預計將從 2024 年的 568.1 億美元成長到 2032 年的 2022.2 億美元，預測期內（2025-2032 年）的複合年成長率為 17.2%。

肺癌、乳癌、膀胱癌和子宮頸癌以及黑色素瘤和何傑金氏淋巴瘤等各種癌症的發生率不斷上升，推動了免疫查核點抑制劑的採用。根據加拿大癌症協會統計，大約 40% 的加拿大人在其一生中會被診斷出患有癌症，並且死於癌症的風險很高，因此對有效的診斷和治療解決方案的需求日益成長。特別是隨著新型免疫查核點抑制劑研究的進展，市場正呈現擴張的跡象。尤其是FDA核准基於遺傳腫瘤特徵的Pembrolizumab ，凸顯了標靶治療的進展。儘管面臨技術進步和社會意識增強等挑戰，免疫查核點抑制劑市場仍顯示出強勁的成長潛力，尤其是在新興國家，為相關人員帶來了光明的前景。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管格局
• 專利分析

免疫查核點抑制劑市場規模（按類型）

• 市場概況
• PD-1 抑制劑
• PD-L1 抑制劑
• CTLA-4 抑制劑
• 其他

免疫查核點抑制劑市場規模（按應用）

• 市場概況
• 肺癌
• 乳癌
• 惡性黑色素瘤
• 膀胱癌
• 何傑金氏淋巴瘤
• 其他

免疫查核點抑制劑市場規模（按分銷管道）

• 市場概況
• 醫院藥房
• 零售藥局
• 網路藥局

免疫查核點抑制劑市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Bristol-Myers Squibb Company（USA）
• Merck & Co., Inc.（USA）
• F. Hoffmann-La Roche AG（Switzerland）
• Regeneron Pharmaceuticals, Inc.（USA）
• AstraZeneca PLC（UK）
• Eli Lilly and Company（USA）
• Sanofi（France）
• BeiGene Ltd.（China）
• Shanghai Junshi Biosciences Ltd.（China）
• GlaxoSmithKline PLC（UK）
• Immutep Ltd.（Australia）
• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Genentech, Inc.（USA）
• Incyte Corporation（USA）
• MacroGenics, Inc.（USA）
• Agenus Inc.（USA）
• Jiangsu Hengrui Medicine Co., Ltd.（China）
• Innovent Biologics, Inc.（China）
• Daiichi Sankyo Company, Limited（Japan）

結論和建議

Global Immune Checkpoint Inhibitors Market size was valued at USD 48.47 billion in 2023 and is poised to grow from USD 56.81 billion in 2024 to USD 202.22 billion by 2032, growing at a CAGR of 17.2% during the forecast period (2025-2032).

The rising incidence of various cancers, including lung, breast, bladder, and cervical cancers, alongside melanomas and Hodgkin lymphoma, is driving the adoption of immune checkpoint inhibitors. According to the Canadian Cancer Society, approximately 40% of Canadians will receive a cancer diagnosis in their lifetime, with a significant mortality risk, fueling the demand for effective diagnostic and therapeutic solutions. The market is set for expansion, particularly with ongoing research into novel immune checkpoint inhibitors. Notably, pembrolizumab's FDA approval, based on genetic tumor features, highlights progress in targeted treatments. While challenges persist, including technological advancements and increased public awareness, the immune checkpoint inhibitors market demonstrates robust growth potential, especially in emerging economies, indicating a promising outlook for stakeholders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Immune Checkpoint Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Immune Checkpoint Inhibitors Market Segments Analysis

Global Immune Checkpoint Inhibitors Market is segmented by Type, Application, Distribution Channel and region. Based on Type, the market is segmented into PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors and Others. Based on Application, the market is segmented into Lung Cancer, Breast Cancer, Melanoma, Bladder Cancer, Hodgkin Lymphoma and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Immune Checkpoint Inhibitors Market

The global immune checkpoint inhibitors market has experienced substantial growth driven by technological innovations and scientific advancements in the field of immunotherapy. In recent years, extensive research has highlighted the essential function of the immune system in fighting cancer, resulting in the creation of therapies that bolster the body's natural immune response to neoplastic cells. As a result, immune checkpoint inhibitors have become a fundamental component of contemporary cancer treatment, specifically targeting and modulating proteins that control immune checkpoints. This evolution in cancer therapy is revolutionizing patient outcomes and expanding the potential for novel treatment options across various malignancies.

Restraints in the Global Immune Checkpoint Inhibitors Market

A major constraint impacting the global immune checkpoint inhibitors market is the steep cost of these therapies. Treatments like pembrolizumab (Keytruda) and nivolumab (Opdivo) carry high price tags due to the extensive investment in research and development, intricate manufacturing methods, and the exorbitant expenses associated with clinical trials. Consequently, a single treatment regimen can amount to tens of thousands of dollars, rendering it unaffordable for numerous patients and healthcare systems, particularly in low- and middle-income nations. This financial burden significantly hampers accessibility to these potentially life-saving therapies for a large segment of the population.

Market Trends of the Global Immune Checkpoint Inhibitors Market

The global immune checkpoint inhibitors market is witnessing significant growth, primarily driven by the rising incidence of cancer, which remains a major health challenge worldwide. As cancer rates continue to surge due to factors such as aging populations and lifestyle changes, the demand for innovative therapies is escalating. Immune checkpoint inhibitors, which have shown promising results in enhancing the immune response against tumors, are becoming essential in oncology treatment regimens. This upward trend is further fueled by ongoing research, the development of novel therapies, and expanding applications in various cancer types, positioning the market for robust expansion in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Immune Checkpoint Inhibitors Market Size by Type & CAGR (2025-2032)

• Market Overview
• PD-1 Inhibitors
• PD-L1 Inhibitors
• CTLA-4 Inhibitors
• Others

Global Immune Checkpoint Inhibitors Market Size by Application & CAGR (2025-2032)

• Market Overview
• Lung Cancer
• Breast Cancer
• Melanoma
• Bladder Cancer
• Hodgkin Lymphoma
• Others

Global Immune Checkpoint Inhibitors Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Immune Checkpoint Inhibitors Market Size & CAGR (2025-2032)

• North America (Type, Application, Distribution Channel)
  • US
  • Canada
• Europe (Type, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Junshi Biosciences Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immutep Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MacroGenics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agenus Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Hengrui Medicine Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innovent Biologics, Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations